Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence; Achieved its primary endpoint; Detailed results from the STEP UP trial are expected to be presented at a scientific conference in 2025 [***Note: compares to patients on highest Eli Lilly's Zepbound dose lost 23% of body weight in 176 weeks]
Friday, January 17, 2025 7:11:55 AMEST
- STEP UP trial shows semaglutide 7.2 mg achieves 20.7% weight loss in 72 weeks, significantly better than 17.5% for 2.4 mg and 2.4% for placebo
- 33.2% on 7.2 mg lost =25% body weight, vs. 16.7% on 2.4 mg and 0% on placebo.
- Treatment policy estimand shows 18.7% weight loss with 7.2 mg, compared to 15.6% with 2.4 mg and 3.9% with placebo.
- Semaglutide 7.2 mg well-tolerated, mainly gastrointestinal side effects, mostly mild to moderate.
When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. In addition, 33.2% of those who received semaglutide 7.2 mg achieved a weight loss of 25% or more after 72 weeks, compared to 16.7% with semaglutide 2.4 mg and 0.0% with placebo.
**Note: 08/20 LLY 176-week SURMOUNT-1 study show tirzepatide (Zepbound and Mounjaro) significantly reduced risk of progression to type 2 diabetes by 94% in adults with pre-diabetes and obesity; Patients on highest Zepbound dose lost 23% of body weight in 176 weeks in the longest continuous study of Zepbound to date
~
- 33.2% on 7.2 mg lost =25% body weight, vs. 16.7% on 2.4 mg and 0% on placebo.
- Treatment policy estimand shows 18.7% weight loss with 7.2 mg, compared to 15.6% with 2.4 mg and 3.9% with placebo.
- Semaglutide 7.2 mg well-tolerated, mainly gastrointestinal side effects, mostly mild to moderate.
When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. In addition, 33.2% of those who received semaglutide 7.2 mg achieved a weight loss of 25% or more after 72 weeks, compared to 16.7% with semaglutide 2.4 mg and 0.0% with placebo.
**Note: 08/20 LLY 176-week SURMOUNT-1 study show tirzepatide (Zepbound and Mounjaro) significantly reduced risk of progression to type 2 diabetes by 94% in adults with pre-diabetes and obesity; Patients on highest Zepbound dose lost 23% of body weight in 176 weeks in the longest continuous study of Zepbound to date